Clinical Trial Update: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study [Phase 2, Phase 3]

View source ↗

Summary

An extension protocol for virologically suppressed HIV-1-infected subjects in the PRO140_CD03 study has been terminated, with results posted on 2025-10-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PRO140 (leronlimab) (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: HIV-1-infection | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-10-30